Docetaxel albumin bound (Cspc Zhongqi )

多西他赛（白蛋白结合型）(中奇制药)

Report date: 2026/04/04 20:00:24

Base Information

Drug NameDocetaxel albumin bound (Cspc Zhongqi )
Drug Alias NameAlbumin-bound docetaxelDocetaxel nanoparticle formulated with human albuminCPO-100DTX-HSANab-docetaxel (Cspc Zhongqi Pharmaceutical) +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitorsTubulin inhibitors
TargetsTubulin
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdShanghai Jmt-Bio IncCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd +[4] 
Inactive CompaniesConjupro Biotherapeutics Inc
Active IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A